Pharmaceutical

Novo Holdings completes Catalent acquisition for $16.5bn

Novo Holdings has completed the previously announced acquisition of Catalent in an all-cash transaction valued at around $16.5bn.

Dec 19, 2024 - 06:00
Novo Holdings completes Catalent acquisition for $16.5bn
Novo Holdings has completed the previously announced acquisition of Catalent in an all-cash transaction valued at around $16.5bn.
Read the original article

Tags:

Previous Article

Corcept’s ALS Modulator Fails to Meet Primary Endpoint in Phase 2 Study

Next Article

Pharma’s data and analytics market forecast to reach to $2.1bn by 2028

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Advent receives US NIH grant for bronchopulmonary dysplasia therapy

Advent receives US NIH grant for bronchopulmonary dyspl...

Jul 19, 2023

China accepts Junshi’s new drug application for NSCLC combo therapy

China accepts Junshi’s new drug application for NSCLC c...

Apr 12, 2023

CD70 CAR-T by UTC Therapeutics for Relapsed Chronic Lym...

Aug 10, 2023